Physician profile
Roberto Ramirez
NPI 1275950321
$22,808.88
in general payments reported to CMS, 2019-2025
23 companies · $4,126 in 2025
The $4,126 reported for 2025 was more than what 91% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,475 · 2020: $3,668 · 2021: $1,223 · 2022: $3,470 · 2023: $1,773 · 2024: $3,075 · 2025: $4,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,500 · Food and Beverage: $3,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,499.95 |
| Food and Beverage | $3,472.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $7,865.89 | 2019-2025 | Acticor 7 Vr-T Dx, Amvia Edge |
| Medtronic, INC. | $5,842.56 | 2021-2025 | Interstim, Venaseal, Azure Xt Dr Mri Surescan |
| Abbott Laboratories | $4,179.78 | 2019-2025 | Aveir, Jot Dx, Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $2,064.77 | 2020-2024 | Latitude Communicator Power Supply, Lux-Dx Insertable Cardiac Monitor, Ingevity+ |
| Amgen INC. | $384.39 | 2019-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $347.51 | 2019-2025 | Lifevest |
| Pfizer INC. | $319.00 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $275.45 | 2020-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $222.99 | 2020-2024 | Farxiga |
| Novartis Pharmaceuticals Corporation | $215.77 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $188.40 | 2021-2025 | Jardiance |
| Tactile Systems Technology INC | $186.70 | 2022-2024 | Flexitouch Plus, Entre Plus |
| Astellas Pharma US INC | $151.99 | 2019-2020 | |
| Lantheus Medical Imaging, INC. | $145.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $106.97 | 2022-2025 | Eliquis, Camzyos |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $95.57 | 2024-2025 | Wegovy, Ozempic |
| Akcea Therapeutics, INC. | $59.49 | 2019 | |
| Cook Medical LLC | $58.13 | 2019 | |
| Philips North America LLC | $30.92 | 2023 | |
| Impulse Dynamics (USA) INC. | $24.19 | 2023 | Optimizer |
| Kiniksa Pharmaceuticals, Ltd. | $16.70 | 2022 | |
| Merck Sharp & Dohme LLC | $15.14 | 2023 | Verquvo |
| Cvrx, INC. | $10.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.